logo-loader
viewEmpyrean Energy PLC

Empyrean Energy says China seismic exploration has exceeded expectations

The seismic programme has unearthed hundreds of millions of barrels of oil potential

offshore oil rigs
Three targets may together have 591mln barrels of crude

Empyrean Energy Plc (LON:EME) told investors that results from a seismic programme offshore China has exceeded expectations.

The explorer, in a stock market statement, said the preliminary mapping of ‘raw seismic 3D data’ confirms the structural validity of Jade and Topaz prospects and identifies a third significant target named Pearl.

READ: Empyrean Energy lands massive China exploration permit

Jade is estimated to have potential to host 103mln barrels of oil, Topaz is estimated to have 365mln barrels and Pearl has 123mln barrels.

Analysis is continuing with full data processing and oil migration studies on-going.

"Empyrean is excited to confirm that, based on our internal preliminary analysis, Block 29/11 contains prospects of truly significant scale and size,” said Tom Kelly, Empyrean chief executive.

“That the three priority targets have a cumulative mean potential to contain 591 million barrels of oil is a great early result from the 3D seismic data recently acquired. 

“We will obtain better resolution and imaging from the full processing of data, a process which is underway and the results of which will be announced in due course, but these early results greatly exceed our expectations and the data quality is excellent."

Quick facts: Empyrean Energy PLC

Price: 8.497 GBX

AIM:EME
Market: AIM
Market Cap: £37.64 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Redx Pharma's chief scientific officer talks grant funding for its fibrosis...

Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project. They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the...

13 minutes ago

2 min read